NOVEL MECHANISM FOR THE SUSTAINED DURABILITY OF PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 MONOCLONAL ANTIBODY LY3015014

Monoclonal antibodies (Mabs) that neutralize proprotein convertase subtilisin-kexin type 9 (PCSK9) cause remarkable LDL cholesterol (LDL-C) lowering in human trials. It was reported that the efficacy is determined by the epitope of the PCSK9 Mab. Here we describe a novel mechanism by which the